Merrill Starts Eyetech Pharmaceuticals with Buy

Analyst Eric Ende says the drugmaker's developmental vision-loss treatment could reach worldwide peak sales of $1 billion

Merrill Lynch initiated coverage on Eyetech Pharmaceuticals (EYET ) with buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.